EVISTA (優雅健)

Therapeutic class 治療性藥物
Anti-Osteoporosis抗骨質疏鬆
Product per pack:
60mg x 28’ Tablets (Film-coated)
 
Ingredient:
Raloxifene HCl
 
Indications:
Treatment & prevention of osteoporosis in postmenopausal women. Reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis and / or at high risk of invasive breast cancer.
 
Dosage:
1 tablet daily, with or without meal.
 
Contraindications:
Women of childbearing potential; active or history of venous thromboembolic events; severe hepatic impairment including cholestasis; severe renal impairment; unexplained uterine bleeding. Endometrial cancer.
 
Special Precaution:
History of stroke or other stroke risk factors e.g. transient ischemic attack or atrial fibrillation. Co-administration with systemic estrogens is not recommended. In patient with history of oral oestrogen-induced hypertriglyceridaemia, monitor serum triglycerides. Complete breast cancer treatment before initiating raloxifene.
 
Adverse Reaction:
Hot flushes, flu syndrome, leg cramps, peripheral oedema, venous thromboembolic events e.g. DVT, pulmonary embolism, retinal vein thrombosis, superficial vein thrombophlebitis.
 
Drug-Drug-Interaction:
Should not be co-administered with cholestyramine. 

Register as Citracium Club members now! 
 
 
© 2010 The International Medical Co. Ltd. All Rights Reserved.
Powered by Smart-Info Limited: Web Design